The US Drug Watchdog says, "We are urging any diabetic who used the diabetes drug called Actos, and have since been diagnosed with bladder cancer to call the Johnson law group for a legal review at 1-800-996-9900." http://www.johnsonlawgroup.com/
(PRWEB) January 07, 2013
The US Drug Watchdog is now saying, "It is counterintuitive to think a diabetes drug, designed to help diabetics deal with their illness, could also be responsible for bladder cancer because of the use of this specific medication, but this is exactly what we are saying. Unfortunately, the use of Actos for diabetes, and an elevated chance of bladder cancer could to be very related."
According to the AP, "The FDA has issued a warning that Actos may be linked to an increased risk of bladder cancer. Meanwhile, both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication." The US Drug Watchdog says, "We now fear bladder cancer, and diabetics using the diabetes drug called Actos is a much bigger problem than we ever dreamed possible, and are urging all Actos users who now have bladder cancer to contact the Johnson Law Group at 1-800-996-9900." http://www.johnsonlawgroup.com/
The US Drug Watchdog says, "One of the biggest problems we have with respect to our drug initiative work, is the average US consumer never hears about a drug recall, or serious side effects related to a specific drug's use. We are attempting to change this very sad fact with aggressive initiatives focused on increasing public awareness, and hopefully suggesting possible help for victims, or the family members of victims." http://USDrugWatchdog.Com
Case number 11cv2406 BEN BGS in the Federal District Court San Diego, CA.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10287139.htm
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.